4.28 USD
-0.07 (-1.61%)
4.36 USD
+0.08 (+1.87%)
VYGR gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for VYGR as it has an excellent financial health rating, but there are worries on the profitability. VYGR does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year VYGR has reported negative net income.
In the past year VYGR has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: VYGR reported negative net income in multiple years.
In the past 5 years VYGR reported 4 times negative operating cash flow.
1.2 Ratios
The Return On Assets of VYGR (-43.97%) is comparable to the rest of the industry.
The Return On Equity of VYGR (-57.67%) is better than 62.17% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -43.97% | ||
| ROE | -57.67% | ||
| ROIC | N/A |
ROA(3y)-2.66%
ROA(5y)-6.13%
ROE(3y)-14.78%
ROE(5y)-19.08%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for VYGR so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
VYGR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VYGR has been increased compared to 1 year ago.
Compared to 5 years ago, VYGR has more shares outstanding
VYGR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -0.64, we must say that VYGR is in the distress zone and has some risk of bankruptcy.
VYGR has a Altman-Z score (-0.64) which is comparable to the rest of the industry.
There is no outstanding debt for VYGR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.64 |
ROIC/WACCN/A
WACC8.78%
2.3 Liquidity
VYGR has a Current Ratio of 6.19. This indicates that VYGR is financially healthy and has no problem in meeting its short term obligations.
VYGR has a Current ratio of 6.19. This is in the better half of the industry: VYGR outperforms 64.79% of its industry peers.
A Quick Ratio of 6.19 indicates that VYGR has no problem at all paying its short term obligations.
VYGR's Quick ratio of 6.19 is fine compared to the rest of the industry. VYGR outperforms 66.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.19 | ||
| Quick Ratio | 6.19 |
3. Growth
3.1 Past
VYGR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -404.23%.
VYGR shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -80.88%.
VYGR shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -5.18% yearly.
EPS 1Y (TTM)-404.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-193.75%
Revenue 1Y (TTM)-80.88%
Revenue growth 3Y28.85%
Revenue growth 5Y-5.18%
Sales Q2Q%-45.73%
3.2 Future
VYGR is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -6.88% yearly.
VYGR is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -8.25% yearly.
EPS Next Y-90.87%
EPS Next 2Y-15.79%
EPS Next 3Y-8.06%
EPS Next 5Y-6.88%
Revenue Next Year-66.69%
Revenue Next 2Y-16.94%
Revenue Next 3Y-9.05%
Revenue Next 5Y-8.25%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for VYGR. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VYGR. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as VYGR's earnings are expected to decrease with -8.06% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.79%
EPS Next 3Y-8.06%
5. Dividend
5.1 Amount
No dividends for VYGR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
4.28
-0.07 (-1.61%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners55.05%
Inst Owner Change-9.18%
Ins Owners0.88%
Ins Owner Change-0.21%
Market Cap237.97M
Revenue(TTM)31.32M
Net Income(TTM)-126.78M
Analysts87.78
Price Target15.3 (257.48%)
Short Float %6.75%
Short Ratio4.99
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.56%
Min EPS beat(2)-6.33%
Max EPS beat(2)11.46%
EPS beat(4)1
Avg EPS beat(4)-17.11%
Min EPS beat(4)-57.86%
Max EPS beat(4)11.46%
EPS beat(8)5
Avg EPS beat(8)79.25%
EPS beat(12)8
Avg EPS beat(12)75.9%
EPS beat(16)10
Avg EPS beat(16)73.9%
Revenue beat(2)1
Avg Revenue beat(2)9.1%
Min Revenue beat(2)-48.55%
Max Revenue beat(2)66.75%
Revenue beat(4)1
Avg Revenue beat(4)-24.46%
Min Revenue beat(4)-62.87%
Max Revenue beat(4)66.75%
Revenue beat(8)5
Avg Revenue beat(8)80.35%
Revenue beat(12)8
Avg Revenue beat(12)85.04%
Revenue beat(16)10
Avg Revenue beat(16)78%
PT rev (1m)-4.26%
PT rev (3m)-4.26%
EPS NQ rev (1m)-4.41%
EPS NQ rev (3m)-4.41%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-0.44%
Revenue NQ rev (3m)-0.44%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 7.6 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.08 | ||
| P/tB | 1.08 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.16
EYN/A
EPS(NY)-1.51
Fwd EYN/A
FCF(TTM)-2.14
FCFYN/A
OCF(TTM)-2.1
OCFYN/A
SpS0.56
BVpS3.95
TBVpS3.95
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -43.97% | ||
| ROE | -57.67% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-2.66%
ROA(5y)-6.13%
ROE(3y)-14.78%
ROE(5y)-19.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.11
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 52.83% | ||
| Cap/Sales | 6.79% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.19 | ||
| Quick Ratio | 6.19 | ||
| Altman-Z | -0.64 |
F-Score2
WACC8.78%
ROIC/WACCN/A
Cap/Depr(3y)62.66%
Cap/Depr(5y)107.17%
Cap/Sales(3y)3.93%
Cap/Sales(5y)4.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-404.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-193.75%
EPS Next Y-90.87%
EPS Next 2Y-15.79%
EPS Next 3Y-8.06%
EPS Next 5Y-6.88%
Revenue 1Y (TTM)-80.88%
Revenue growth 3Y28.85%
Revenue growth 5Y-5.18%
Sales Q2Q%-45.73%
Revenue Next Year-66.69%
Revenue Next 2Y-16.94%
Revenue Next 3Y-9.05%
Revenue Next 5Y-8.25%
EBIT growth 1Y-1280.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-74.77%
EBIT Next 3Y-8.22%
EBIT Next 5Y-12.11%
FCF growth 1Y-238.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-230.43%
OCF growth 3YN/A
OCF growth 5YN/A
VOYAGER THERAPEUTICS INC / VYGR FAQ
What is the fundamental rating for VYGR stock?
ChartMill assigns a fundamental rating of 2 / 10 to VYGR.
Can you provide the valuation status for VOYAGER THERAPEUTICS INC?
ChartMill assigns a valuation rating of 0 / 10 to VOYAGER THERAPEUTICS INC (VYGR). This can be considered as Overvalued.
What is the profitability of VYGR stock?
VOYAGER THERAPEUTICS INC (VYGR) has a profitability rating of 1 / 10.
What is the financial health of VOYAGER THERAPEUTICS INC (VYGR) stock?
The financial health rating of VOYAGER THERAPEUTICS INC (VYGR) is 7 / 10.
What is the earnings growth outlook for VOYAGER THERAPEUTICS INC?
The Earnings per Share (EPS) of VOYAGER THERAPEUTICS INC (VYGR) is expected to decline by -90.87% in the next year.